GlassScriptPhysician profile
Sanjay J Patel
NPI 1447227319
$6,914.32
in general payments reported to CMS, 2019-2025
49 companies · $1,551 in 2025
The $1,551 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $220 · 2021: $12.28 · 2022: $802 · 2023: $1,687 · 2024: $1,655 · 2025: $1,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,892.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $968.36 | 2019-2025 | |
| Novo Nordisk INC | $738.84 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $731.69 | 2021-2025 | |
| Lilly USA, LLC | $546.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $461.27 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $274.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $260.88 | 2022-2025 | |
| Amgen INC. | $256.12 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $204.70 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $200.58 | 2019-2025 | Veozah |
| Abbott Laboratories | $186.30 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $154.37 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.08 | 2019-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $129.20 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $126.99 | 2024-2025 | Auvelity |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.